

Ovarian Cancer™

U P D A T E

Conversations with Oncology Investigators
Bridging the Gap between Research and Patient Care

Select Publications

A randomized phase II evaluation of single-agent bevacizumab (IND #7921) (NSC #704865) and combination bevacizumab with fosbretabulin tromethamine (CA4P) (NSC #752293) in the treatment of recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. **NCT01305213**

Armstrong DK et al. **Intraperitoneal cisplatin and paclitaxel in ovarian cancer.** *N Engl J Med* 2006;354(1):34-43. **Abstract**

Aghajanian C et al. **OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC).** *Proc ASCO* 2011;Abstract LBA5007.

Burger RA et al. **Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study.** *Proc ASCO* 2010;Abstract LBA1.

Coleman RL et al. **Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.** *Lancet Oncol* 2011;12(12):1109-17. **Abstract**

Colombo N et al. **Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: Preliminary results of a pilot study.** *Proc ASCO* 2008;Abstract 14598.

Friedlander M et al. **A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.** *Gynecol Oncol* 2010;119(1):32-7. **Abstract**

Fujiwara K et al. **A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer.** *Jpn J Clin Oncol* 2011;41(2):278-82. **Abstract**

Gadducci A et al. **Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: Results of a multicenter retrospective Italian study.** *J Clin Oncol* 2005;23(4):751-8. **Abstract**

Gelmon KA et al. **Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.** *Proc ASCO* 2010;Abstract 3002.

GOG-0252: A phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and primary peritoneal carcinoma NCI-supplied agent(s): Bevacizumab. **NCT00951496**

Goss PE et al. **Exemestane for breast-cancer prevention in postmenopausal women.** *N Engl J Med* 2011;364(25):2381-91. **Abstract**

Karlan BY et al. **Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma.** *Proc ASCO* 2010;Abstract 5000.

Kristensen G et al. **Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.** *Proc ASCO* 2011;Abstract LBA5006.

Ledermann JA et al. **A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC).** *Proc ASCO* 2009;Abstract 5501.

Mahner S et al. **Prognostic impact of the time interval between primary surgery and start of first-line chemotherapy in patients with advanced ovarian cancer: Analysis of prospective randomized phase III trials.** *Proc ASCO 2009*;Abstract 5514.

Phase I/II study of cediranib and olaparib in combination for treatment of recurrent papillary-serous ovarian, fallopian tube or peritoneal cancer or for treatment of recurrent triple-negative breast cancer. **NCT01116648**

Ramasubbaiah R et al. **Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.** *Gynecol Oncol* 2010;123(3):499-504. **Abstract**

Zweifel M et al. **Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.** *Ann Oncol* 2011;22(9):2036-41. **Abstract**